Corticortophin releasing factor 2 receptor agonist treatment significantly slows disease progression in mdx mice

BMC Medicine

Volumn 5, Issue , 2007, Pages

  Hinkle, Richard T ^a   Lefever, Frank R ^a   Dolan, Elizabeth T ^a   Reichart, Deborah L ^a   Dietrich, Jefferey A ^a   Gropp, Kathryn E ^a   Thacker, Robert I ^b   Demuth, Jeffrey P ^a   Stevens, Paula J ^a   Qu, Xiaoyan A ^a   Varbanov, Alex R ^a   Wang, Feng ^a   Isfort, Robert J ^a  

^a PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOTROPIN RELEASING FACTOR DERIVATIVE; CORTICOTROPIN RELEASING FACTOR RECEPTOR 2; CORTICOTROPIN RELEASING FACTOR RECEPTOR 2 AGONIST; DYSTROPHIN; GLUCOCORTICOID; PG 873637; PREDNISONE; UNCLASSIFIED DRUG; CORTICOTROPIN RELEASING FACTOR RECEPTOR; CRF RECEPTOR TYPE 2;

AGING; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY MASS; CELL INFILTRATION; CIRCADIAN RHYTHM; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIAPHRAGM PARALYSIS; DISEASE COURSE; DUCHENNE MUSCULAR DYSTROPHY; EXTRACELLULAR MATRIX; GENE EXPRESSION PROFILING; IMMUNOCOMPETENT CELL; METABOLIC PARAMETERS; MONOTHERAPY; MOUSE; MYOFIBROSIS; NONHUMAN; ANIMAL; BIOLOGICAL MODEL; DISEASE MODEL; DRUG POTENTIATION; GENE EXPRESSION REGULATION; GENETICS; MALE; METABOLISM; MUSCLE; MUTATION; PATHOLOGY; TIME; X CHROMOSOME LINKED MUSCULAR DYSTROPHIC MOUSE;

ANIMALS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DYSTROPHIN; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; MALE; MICE; MICE, INBRED MDX; MODELS, BIOLOGICAL; MUSCLES; MUSCULAR DYSTROPHY, DUCHENNE; MUTATION; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; TIME FACTORS;

EID: 34547750918     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/1741-7015-5-18     Document Type: Article

References (32)

1. Engel AG Yamamoto M Fischbeck KH Dystrophinopathies. Myology Columbus, OH: McGraw-Hill Engel AG, Franzini-Armstrong C 1994:1133-1187
2. Nowak KJ Davies KE Duchenne muscular dystrophy and dystrophin: pathogenesis and opportunities for treatment. EMBO Reports 2004, 5:872-876 1299132 15470384 10.1038/sj.embor.7400221
3. Blake DJ Weir A Newey SE Davies KE Function and genetics of dystrophin and dystrophin-related proteins in muscle. Physiol Rev 2002, 82:291-329 11917091
4. Khurana TS Davies KE Pharmacological strategies for muscular dystrophy. Nat Rev Drug Disc 2003, 2:379-390 10.1038/nrd1085
5. Cossu G Sampaolesi M New therapies for muscular dystrophy: Cautious optimism Trends Mol Med 2004, 10:516-520 10.1016/j.molmed.2004.08.007 15464452
6. Muntoni F Fisher I Morgan JE Abraham D Steroids in Duchenne muscular dystrophy: From clinical trials to genomic research. Neuromuscul Disord 2002, 1:S162-S165 10.1016/S0960-8966(02)00101-3
7. Bogdanovich S Perkins KJ Krag TOB Khurana TS Therapeutics for Duchenne muscular dystrophy: Current approaches and future directions. J Mol Med 2004, 82:102-115 10.1007/s00109-003-0484-1 14673527
8. Durbeej M Campbell KP Muscular dystrophies involving the dystrophin-glycoprotein complex: An overview of current mouse models. Curr Opin Genet Dev 2002, 12:349-361 10.1016/S0959-437X(02)00309-X 12076680
9. Collins CA Morgan JE Duchenne's muscular dystrophy: Animal models used to investigate pathogenesis and develop therapeutic strategies. Int J Exp Pathol 2003, 84:165-172 10.1046/j.1365-2613.2003.00354.x 14632630
10. Dupont-Versteegden EE McCarter RJ Differential expression of muscular dystrophy in diaphragm versus hindlimb muscles of mdx mice. Muscle Nerve 1992, 15:1105-1110 10.1002/mus.880151008 1406767
11. Louboutin JP Fichter-Gagnepain V Thaon E Fardeau M Morphometric analysis of mdx diaphragm muscle fibres: Comparison with hindlimb muscles. Neuromuscul Disord 1993, 3:463-469 10.1016/0960-8966(93)90098-5 8186695
12. Stedman HH Sweeney HL Leferovich JM Sladky JT Kelly AM The mdx mouse diaphragm reproduces the degenerative changes of Duchenne muscular dystrophy. Nature 1991, 352:536-538 10.1038/352536a0 1865908
13. Hinkle RT Donnelly E Cody DB Bauer MB Isfort RJ Urocortin II treatment reduces skeletal muscle mass and function loss during atrophy and increases nonatrophying skeletal muscle mass and function. Endocrinology 2003, 144:4939-4946 10.1210/en.2003-0271 12960070
14. Hinkle RT Donnelly E Cody DB Bauer MB Sheldon RJ Isfort RJ Corticotropin releasing factor 2 receptor agonists reduce the denervation-induced loss of rat skeletal muscle mass and force and increase non-atrophying skeletal muscle mass and force. J Muscle Res Cell Motil 2005, 25:539-547 10.1007/s10974-004-4088-3
15. Hinkle RT Donnelly E Cody DB Samuelsson S Lange JS Bauer MB Tarnopolsky M Sheldon RJ Coste SC Tobar E Stenzel-Poore MP Isfort RJ Activation of the CRF2 receptor modulates skeletal muscle mass under physiological and pathological conditions. Am J Physiol Endocrinol Metab 2003, 285:E889-E898 12959937
16. Isfort RJ Wang F Tscheiner M Donnelly E Bauer MB Lefever F Hinkle RT Mazur AW Discovery of corticotropin releasing factor 2 receptor selective sauvagine analogues for treatment of skeletal muscle atrophy. J Med Chem 2005, 13:262-263 10.1021/jm049490m
17. Mazur AW Wang F Tscheiner M Donnelly E Isfort RJ Determinants of corticotrophin releasing factor receptor selectivity of corticotrophin releasing factor related peptides. J Med Chem 2004, 47:3450-3454 10.1021/ jm049883l 15189041
18. Mazur AW Wang F Tscheiner M Donnelly E Isfort RJ Sauvagine analogs selective for corticotrophin releasing factor 2 receptor: Effects of substitutions at positions 35 and 39 on CRFR selectivity. Peptides 2005, 26:887-891 10.1016/j.peptides.2004.12.013 15808919
19. Hudecki MS Pollina CM Granchelli JA Daly MK Byrnes T Wang JC Hsiao JC Strength and endurance in the therapeutic evaluation of prednisolone-treated mdx mice. Res Commun Chem Pathol Pharmacol 1993, 79:45-60 8434132
20. Mendell JR Moxley RT Griggs RC Brooke MH Fenichel GM Miller JP King W Signore L Pandya S Florence J Shierbecker J Robison J Kaiser K Mandel S Arfken C Gilder B Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy. N Engl J Med 1989, 320:1592-1597 2657428
21. Yoshida M Hama H Ishikawa-Sakurai M Imamura M Mizuno Y Araishi K Wakabayashi-Takai E Noguchi S Sasaoka T Ozawa E Biochemical evidence for association of dystrobrevin with sarcoglycan-sarcospan complex as a basis for understanding sarcoglycanopathy. Hum Mol Genet 2000, 9:1033-1040 10.1093/hmg/9.7.1033 10767327
22. Harcourt LJ Holmes AG Gregorevic P Schertzer JD Stupka N Plant DR Lynch GS Interleukin-15 administration improves diaphragm muscle pathology and function in dystrophic mdx mice. Am J Pathol 2005, 166:1131-1141 1602390 15793293
23. Bell-Pedersen D Cassone VM Earnest DJ Golden SS Hardin PE Thomas TL Zoran MJ Circadian rhythms from multiple oscillators: Lessons from diverse organisms. Nat Rev Genet 2005, 6:544-556 10.1038/nrg1633 15951747
24. Ueda HR Hayashi S Chen W Sano M Machida M Shigeyoshi Y Iino M Hashimoto S System-level identification of transcriptional circuits underlying mammalian circadian clocks. Nat Genet 2005, 37:187-192 10.1038/ng1504 15665827
25. Duffield GE DNA microarray analyses of circadian timing: The genomic basis of biological time. J Neuroendocrinol 2003, 15:991-1002 10.1046/ j.1365-2826.2003.01082.x 12969245
26. Zambon AC McDearmon EL Salomonis N Vranizan KM Johansen KL Adey D Takahashi JS Schambelan M Conklin BR Time- and exercise-dependent gene regulation in human skeletal muscle. Gen Biol 2003, 4:R61 10.1186/ gb-2003-4-10-r61
27. Turek FW Joshu C Kohsaka A Lin E Ivanova G McDearmon E Laposky A Losee-Olson S Easton A Jensen DR Eckel RH Takahashi JS Bass J Obesity and metabolic syndrome in circadian clock mutant mice. Science 2005, 308:1043-1045 10.1126/science.1108750 15845877
28. Rutter J Reick M McKnight SL Metabolism and the control of circadian rhythm. Ann Rev Biochem 2002, 71:307-331 10.1146/ annurev.biochem.71.090501.142857 12045099
29. Rutter J Reick M Wu LC McKnight SL Regulation of clock and NPAS2 DNA binding by the redox state of NAD cofactors. Science 2001, 293:510-514 10.1126/science.1060698 11441146
30. Pelleymounter MA Joppa M Ling N Foster AC Behavioral and neuroendocrine effects of the selective CRF2 receptor agonists urocortin II and urocortin III. Peptides 2004, 25:659-666 10.1016/j.peptides.2004.01.008 15165722
31. Balsalobre A Brown SA Marcacci L Tronche F Kellendonk C Reichardt HM Schutz G Schibler U Resetting of circadian time in peripheral tissues by glucocorticoid signaling. Science 2000, 289:2344-2347 10.1126/ science.289.5488.2344 11009419
32. Gannon RL Millan MJ The corticotrophin-releasing factor (CRF)(1) receptor antagonists CP154,526 and DMP695 inhibit light-induced phase advances of hamster circadian activity rhythms. Brain Res 2006, 1083:92-102 10.1016/j.brainres.2006.02.017